An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
SOPHiA GENETICS to Present at the J.P. Morgan 2023 Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
SOPHiA GENETICS (NASDAQ: SOPH) announced that CEO Dr. Jurgi Camblong will present at the J.P. Morgan 2023 Healthcare Conference on January 10, 2023, at 8:15 a.m. PST in San Francisco. Interested parties can access the live webcast via the company's Investor Relations page, with a replay available for two weeks post-event. SOPHiA GENETICS is a pioneer in data-driven medicine, offering the SOPHiA DDM ™ Platform for analyzing complex multimodal data.
Positive
None.
Negative
None.
BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)--
SOPHiA GENETICS SA (NASDAQ: SOPH) today announced that Dr. Jurgi Camblong, Chief Executive Officer and Co-Founder, is scheduled to present at the J.P. Morgan 2023 Healthcare Conference on Tuesday, January 10, 2023, at 8:15 a.m. PST in San Francisco.
Live, listen-only webcasts of this presentation can be accessed by visiting the Investors section of the SOPHiA GENETICS website at ir.sophiagenetics.com. A replay of the webcast will be available shortly after the conclusion of the presentation and archived on the company's website for two weeks following the presentation.
About SOPHiA GENETICS
SOPHiA GENETICS (NASDAQ: SOPH) is a cloud-native software company in the healthcare space dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM ™ Platform, a software platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM ™ Platform and related solutions, products, and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, please visit http://www.SOPHiAGENETICS.com or follow SOPHiA GENETICS on Twitter (@SOPHiAGENETICS).